Brief: Clover Health Investments Q2 Revenue USD 478 Million Vs. IBES Estimate USD 468.3 Million

Clover Health Investments

05/08/2025 21:05

Overview

Clover Health Q2 2025 rev grows 34% yr/yr, beating analyst expectations, per LSEG data

Adjusted EBITDA for Q2 beats consensus, reaching $17 mln

Company reports GAAP net loss of $11 mln for Q2

Outlook

Clover Health maintains full-year insurance revenue guidance at $1.800 bln - $1.875 bln

Company improves full-year Adjusted SG&A to $335 mln - $345 mln

Clover Health expects Insurance BER between 88.5% - 89.5%

Company anticipates average Medicare Advantage membership of 104,000 - 108,000

Result Drivers

TECHNOLOGY-FIRST MODEL - Co attributes growth to technology-first model, focusing on affordability and AI-driven clinical recommendations, per CEO Andrew Toy

MEMBERSHIP GROWTH - Medicare Advantage membership increased by 32% yr/yr, reaching 106,323 members

CLOVER ASSISTANT IMPACT - Co reports improved health outcomes with Clover Assistant technology, citing fewer hospitalizations and readmissions for COPD

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$478 mln
$468.30 mln (4 Analysts)
Q2 Net Income
-$11 mln
Q2 Adjusted EBITDA
Beat
$17 mln
$16.30 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the managed healthcare peer group is "buy."

Wall Street's median 12-month price target for Clover Health Investments Corp is $4.50, about 36% above its August 4 closing price of $2.88

Press Release: ID:nGNX341MNy

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)